15 Nov. 2023  J. Molner AS Enters the US Market with Hydrocortisone Butyrate Lotion, 0.1%

15 Sep. 2023  J. Molner AS Consolidated Unaudited Interim Report for the First 6 Months of 2023 and increase of The J. Molner Company OÜ voluntary reserve

6 Sep. 2023  J. Molner Signs Licensing Agreement for Five Approved Drugs in the US

2 Aug. 2023  Restructuring in the employee structure of J.Molner AS subsidiary The J. Molner Company OÜ

13 Jul. 2023  J. Molner submits drug application to U.S Food and Drug Administration (FDA)

8 Jun. 2023  J. Molner AS Announces Historic Milestone: Receives Health Canada Approval for its First Drug, Norepinephrine Bitartrate Injection

28 Apr. 2023  Restructuring in the employee structure of J.Molner AS subsidiary The J. Molner Company OÜ

20 Apr. 2023  J.Molner AS Resolutions of annual general meeting

10 Apr. 2023 J.Molner concludes loan agreement extending the existing credit facility of The J. Molner Company OÜ

6 Apr. 2023 J. Molner announces licensing agreement for generic injectable drugs with Juno Pharmaceuticals in Canada

28 Mar. 2023  Notice of calling the annual general meeting of the shareholders

28 Mar. 2023  J.Molner submits second drug to Health Canada

17 Mar. 2023  J.Molner AS comments on the observation status applied on J.Molner AS shares on March 10, 2023 by Nasdaq Tallinn

10 Mar. 2023 J.Molner AS Audited Annual Reports 2022

10 Mar. 2023 J.Molner AS Unaudited Interim Reports 2022

9 Jan. 2023  J. Molner AS executes planned reorganization transaction